Copper toxicity is theoretically possible but extremely unlikely from topical OTC products, which contain copper peptides at carefully formulated concentrations
risk difference: 0.7% (95% confidence interval (CI): 1.2% to 0.2%)
Most BPC-157 preclinical work uses dosages around 10 mcg/kg administered intraperitoneally or subcutaneously in rodents, with study durations ranging from single administration to 14-day periods
Research has reported that blocking NNMT was associated with increased energy expenditure and reduced fat mass in animal studies, independent of diet or exercise changes
40 % of the tracer remained in the carcass, 37 % was found in urine and 15 % as carbon dioxide
FD has received occasional consulting fees/honoraria and travel grants from BMS-Pfizer Alliance, Amgen, AstraZeneca, Bayer, Bouchara-Recordati, Bristol Myers Squibb, Boehringer Ingelheim, Menarini, Merck Sharp & Dohme, Novartis, Novo Nordisk, Organon, Pfizer, Sanofi, and Servier